IL122385A - Composition for sustained release of human growth hormone - Google Patents

Composition for sustained release of human growth hormone

Info

Publication number
IL122385A
IL122385A IL12238596A IL12238596A IL122385A IL 122385 A IL122385 A IL 122385A IL 12238596 A IL12238596 A IL 12238596A IL 12238596 A IL12238596 A IL 12238596A IL 122385 A IL122385 A IL 122385A
Authority
IL
Israel
Prior art keywords
composition
sustained release
hgh
biologically active
polymer
Prior art date
Application number
IL12238596A
Other languages
English (en)
Other versions
IL122385A0 (en
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/473,544 external-priority patent/US5654010A/en
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of IL122385A0 publication Critical patent/IL122385A0/xx
Publication of IL122385A publication Critical patent/IL122385A/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL12238596A 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone IL122385A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/473,544 US5654010A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
US08/477,725 US5667808A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
PCT/US1996/008086 WO1996040072A2 (en) 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone

Publications (2)

Publication Number Publication Date
IL122385A0 IL122385A0 (en) 1998-06-15
IL122385A true IL122385A (en) 2001-01-11

Family

ID=27044171

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12238596A IL122385A (en) 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone

Country Status (21)

Country Link
EP (1) EP0831787B1 (pt)
JP (1) JPH11506740A (pt)
CN (1) CN1102854C (pt)
AT (1) ATE204468T1 (pt)
AU (1) AU708756B2 (pt)
BR (1) BR9608542A (pt)
CA (1) CA2223436A1 (pt)
CZ (1) CZ288147B6 (pt)
DE (1) DE69614685T2 (pt)
DK (1) DK0831787T3 (pt)
ES (1) ES2161366T3 (pt)
HU (1) HUP9900870A3 (pt)
IL (1) IL122385A (pt)
MX (1) MX9709698A (pt)
NO (1) NO316104B1 (pt)
NZ (1) NZ310644A (pt)
PL (1) PL184531B1 (pt)
PT (1) PT831787E (pt)
RU (1) RU2161502C2 (pt)
SK (1) SK281571B6 (pt)
WO (1) WO1996040072A2 (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE268591T1 (de) * 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
AU7871298A (en) 1996-12-20 1998-07-17 Takeda Chemical Industries Ltd. Method of producing a sustained-release preparation
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
PT1076703E (pt) 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1978029A3 (en) 1999-06-15 2008-10-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
CA2496312A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
EP2163625B1 (en) 1999-12-23 2014-05-21 Genentech, Inc. IL-17 and IL-17R homologous polypeptides and therapeutic uses thereof
CN101643733A (zh) 2000-01-13 2010-02-10 杰南技术公司 新的stra6多肽
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
ATE328605T1 (de) 2000-03-24 2006-06-15 Genentech Inc Verwendung von insulin zur behandlung von knorpelkrankheiten
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
US7271150B2 (en) 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
IL159048A0 (en) 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
US20060035278A9 (en) 2003-06-06 2006-02-16 Genentech, Inc. Methods and compositions for modulating HGF/Met
PL1641822T3 (pl) 2003-07-08 2013-10-31 Genentech Inc Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
RU2006124743A (ru) 2003-12-11 2008-01-20 Дженентек, Инк. (Us) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
EP2289911A3 (en) 2004-03-30 2011-03-30 NsGene A/S Therapeutic use of a growth factor, NsG33
EP2446894A3 (en) 2004-10-27 2013-02-20 University Of Denver Adrenocorticotropic hormone analogs and related methods
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
BRPI0518999A2 (pt) 2004-12-10 2008-12-23 Talima Therapeutics Inc composiÇÕes e mÉtodos para tratar condiÇÕes da unidade da unha
JP2008541781A (ja) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
CA2873914A1 (en) 2005-06-21 2007-01-04 Xoma (Us) Llc Il-1.beta. binding antibodies and fragments thereof
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1917355B1 (en) 2005-08-24 2010-12-08 The Rockefeller University Ply-gbs mutant lysins
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP1973942B1 (en) 2005-12-22 2011-02-09 Genentech, Inc. Recombinant production of heparin binding proteins
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
WO2007109376A2 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
US7695928B2 (en) 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
EP2010662A2 (en) 2006-04-19 2009-01-07 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
RU2493868C2 (ru) * 2006-08-31 2013-09-27 Новартис Аг ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
MX2009006709A (es) 2006-12-20 2009-07-02 Xoma Technology Ltd Tratamiento de enfermedades relacionadas con il-1beta.
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
EP2488643A4 (en) 2009-10-15 2013-07-03 Hoffmann La Roche CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
JP5878477B2 (ja) 2010-01-15 2016-03-08 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 骨の治癒を加速するためのバナジウム化合物の使用
HRP20190751T1 (hr) 2010-03-22 2019-06-14 F. Hoffmann - La Roche Ag Pripravci i postupci korisni za stabilizaciju formulacija koje sadrže proteine
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
KR101924653B1 (ko) 2010-06-24 2018-12-03 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
JP6149226B2 (ja) 2010-10-01 2017-06-21 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛及び幻肢痛の処置
CA2814030C (en) 2010-10-08 2019-04-30 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
CN102875683B (zh) * 2011-07-11 2014-06-11 旭华（上海）生物研发中心有限公司 长效重组人生长激素的Fc融合蛋白
MY197851A (en) 2011-10-31 2023-07-20 Genentech Inc Antibody formulations
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
JP2016514024A (ja) 2013-03-14 2016-05-19 ハラックス，インコーポレイテッド 爪部の感染症、疾患または障害の治療方法
WO2014152157A2 (en) 2013-03-15 2014-09-25 Bethisrael Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105792851B (zh) 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
KR102357968B1 (ko) 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
ES2845924T3 (es) 2013-10-15 2021-07-28 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2015095406A1 (en) 2013-12-18 2015-06-25 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
WO2018075807A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
EP3807644A4 (en) 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
AR118536A1 (es) 2019-04-01 2021-10-20 Genentech Inc Composiciones y métodos para estabilizar formulaciones que contienen proteína
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
AU2022264339A1 (en) 2021-04-28 2023-11-09 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
US20240218033A1 (en) 2021-05-06 2024-07-04 Hoba Therapeutics Aps Prevention and treatment of chemotherapy-induced neuropathic pain
CA3221611A1 (en) 2021-06-09 2022-12-15 Weijun Shen Long-acting dual gip/glp-1 peptide conjugates and methods of use
CN118488846A (zh) 2021-12-10 2024-08-13 霍巴治疗公司 伤害性疼痛的治疗
CN118354793A (zh) 2022-04-29 2024-07-16 普瑞诺生物科技公司 用于治疗嗜酸性粒细胞驱动的疾病和病症的方法和组合物
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
EP0674506B1 (en) * 1992-12-02 2000-08-23 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
ATE197550T1 (de) * 1993-02-23 2000-12-15 Genentech Inc Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
CA2196184C (en) * 1994-09-09 2009-06-09 Yasutaka Igari Sustained release preparation containing metal salt of a peptide

Also Published As

Publication number Publication date
PT831787E (pt) 2002-02-28
CZ390797A3 (cs) 1998-07-15
SK167197A3 (en) 1998-06-03
AU708756B2 (en) 1999-08-12
HK1009089A1 (en) 1999-09-10
CN1102854C (zh) 2003-03-12
CN1187120A (zh) 1998-07-08
NZ310644A (en) 1999-08-30
RU2161502C2 (ru) 2001-01-10
CZ288147B6 (en) 2001-05-16
DE69614685D1 (de) 2001-09-27
HUP9900870A2 (hu) 1999-09-28
BR9608542A (pt) 1999-11-30
MX9709698A (es) 1998-07-31
WO1996040072A3 (en) 1997-01-23
EP0831787A2 (en) 1998-04-01
NO975708L (no) 1998-02-05
JPH11506740A (ja) 1999-06-15
ES2161366T3 (es) 2001-12-01
EP0831787B1 (en) 2001-08-22
PL323832A1 (en) 1998-04-27
HUP9900870A3 (en) 2001-04-28
PL184531B1 (pl) 2002-11-29
NO975708D0 (no) 1997-12-05
CA2223436A1 (en) 1996-12-19
DE69614685T2 (de) 2002-06-27
WO1996040072A2 (en) 1996-12-19
AU6146996A (en) 1996-12-30
ATE204468T1 (de) 2001-09-15
DK0831787T3 (da) 2001-12-17
NO316104B1 (no) 2003-12-15
IL122385A0 (en) 1998-06-15
SK281571B6 (sk) 2001-05-10

Similar Documents

Publication Publication Date Title
IL122385A (en) Composition for sustained release of human growth hormone
MX9709699A (es) Composicion para la liberacion sostenida de eritropoyetina no agregada.
DE3853853T2 (de) Verabreichungsformen für Pharmaka.
DE3685958T2 (de) Durch ultraschall gesteuerte polymere vorrichtungen zur wirkstoffabgabe.
DE3689983T2 (de) Arzneimittel mit langsamer Wirkstofffreisetzung.
EP1570823A3 (en) Substained analgesia achieved with buprenorphine
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
CA2474698A1 (en) Polymer-based compositions for sustained release
AU5962496A (en) Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5972384A (en) Use of biologically active glass as a drug delivery system
JPH07187994A (ja) 薬物放出制御製剤
EP1011637A4 (en) MODULATION OF DRUG LOAD IN MULTIFICULAR LIPOSOMES
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
US5342622A (en) Subdermal biocompatible implants
GB9313484D0 (en) Drug system ii
SK281461B6 (sk) Kolagénový prípravok na riadené uvoľňovanie účinných látok
AU5673399A (en) Compositions and methods for treating intracellular infections
EP0050650A1 (en) Prolonged action drug formulation
EP0719555A2 (de) Verwendung von Melatonin zur Herstellung peroraler pulsatiler Arzneiformen
JPH0513130B2 (pt)
JPH06507634A (ja) 局所炎症反応の放出制御型薬物送達手段としての設計
RU97115937A (ru) Применение изосорбид-5-мононитрата

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees